Abstract: The present invention relates to methods for characterization of bacterial skin microbiota to provide diagnostic, therapeutic, and preventive measures for alleviating skin conditions. In certain embodiments, the invention relates to characterization of bacterial skin microbiota associated with psoriasis and related diagnostic, therapeutic, and preventive measures for alleviating psoriasis. These methods will be useful for detecting, diagnosing, and monitoring individuals who have or are at risk of certain skin conditions.

Abstract: The present invention generally relates to the field of probiotic micro-organisms, in particular to the field of non-replicating probiotic micro-organisms. Embodiments of the present invention relate to compositions comprising probiotic micro-organisms that were rendered non-replicating by extrusion. Such compositions may be used to treat or prevent disorders that are related to a compromised immune system.

Abstract: Bacteria which co-express protease inhibitors and protease sensitive therapeutic agents, which are surface displayed, secreted and/or released and result in their localized production and maintenance within a target tissue and inactivation outside of the target tissue, thereby increasing therapeutic activity and reducing the systemic toxicity. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. Protease sensitivity may be further accomplished by engineering protease degradation sites within the therapeutic agents, further enhancing the inactivation outside of the target tissue while retaining activity within the target tissue through co-expression of a protease inhibitor. Novel chimeric proteins secreted by bacteria, including chimeric toxins targeted to neoplastic cells, tumor matrix cells and cells of the immune system, and combination therapies of these protease inhibitor:chimeric toxin-expressing bacteria together with small-molecule and biologic agents are also described.

Abstract: The invention provides a screening method for identifying an insect-specific TRPA1 modulator by comparing modulation of an insect TRPA1 and a mammalian TRPA1. The invention further provides method of insect control by applying to an insect a insect-specific TRPA1 modulator identified by the screening method.

Abstract: The present invention is directed to a compound which induces a physiological dispersion response in bacterial cells in a biofilm. The present invention is also directed to compositions containing this compound, methods of isolating the compound, and uses thereof.

Abstract: The purpose of the present invention is to provide a technique whereby the flavor of products such as fermented milk that use the Bifidobacterium bacteria can be improved while maintaining the effect of the Rubus suavissimus S. Lee for improving the viability of the Bifidobacterium bacteria. Provided is a fermented food that includes: a Rubus suavissimus S. Lee essence obtained as a concentrate through electrodialyzing a Rubus suavissimus S. Lee extract added with an inorganic salt; and bacteria of the genus Bifidobacterium. Also provided is a method for producing such fermented foods.

Abstract: The present invention provides novel antimicrobial bacteria strains and uses thereof to prepare novel antimicrobial agents. Also provided are the novel antimicrobial agents.

Abstract: A cellular constituent is lysed from, produced by and/or isolated from one or more bacteria from the genus Bacteroides, and the cellular constituent, a derivative thereof, and/or one or more bacteria from the genus Bacteroides, or a modified form thereof, is employed in compositions and methods for modulating an inflammatory response.

Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release.

Abstract: Compositions and methods for controlling molluscs, members of the Gastropoda and Bivalvia classes which includes but is not limited to lactones, lactams, carbamates, amides, and/or carboxylic acid containing compounds as active ingredients and/or compounds derived from Pseudomonas and/or Erwinia. Also provided are methods and compositions for increasing the efficacy of chemical and biological control for invasive molluscs in open waters, power plants, and drinking water treatment facilities under coldwater conditions.

Abstract: The invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium: (i) from 0.01% to 10% by weight, relative to the total weight of the composition, of one or more compounds chosen from ellagic acid, ethers thereof and ellagic acid salts or ethers thereof, in a content ranging (ii) one or more extracts of one or more non-photosynthetic, non-fruiting filamentous bacteria, and (iii) one or more surfactants chosen from anionic and/or amphoteric or zwitterionic surfactants. The invention also relates to a cosmetic treatment process using such a composition, and to the use of this composition for eliminating and/or reducing the amount of dandruff on the hair and the scalp.

Abstract: Disclosed is a method for the treatment and/or diagnosis of cancer, using bacterial cell-derived microvesicles, which is highly effective in cancer therapy with a significant reduction in side effects. Also, a method is provided for delivering of a drug therapeutic or diagnostic for a disease, using bacterial cell-derived microvesicles loaded with the drug, thereby treating and diagnosing the disease effectively and specifically.

Abstract: Methods are disclosed for the prevention and/or treatment of certain gastrointestinal (GI) diseases, such as Johne's Diseases (JD) in animals and Crohn's Disease (CD) in human. Administration of certain probiotic bacteria, such as lactic acid producing bacteria, to animals helps inhibit GI infection by Mycobacterium avium subsp. paratuberculosis (MAP). MAP is the primary pathogenic agent suspected of causing various inflammatory bowel diseases in cattle or humans.

Abstract: Liposomes with cosmetic and/or dermopharmaceutical ingredients for the care of the skin, scalp and/or hair and their use in washing agents and/or sprays for the treatment of textile materials.

Abstract: Means, compositions, and uses for triggering exocytosis of lysosomes in living cells. During exocytosis, lysosomes travel to the plasma membrane of the cell and dump their contents outside of the cells, thus removing accumulations of harmful, reactive metabolic by-products, such as lipofuscin. Consequently, cells function better, thus improving their vitality and the vitality of people, animals, and cell cultures. Degenerative diseases can be prevented or reversed. Embodied methods include electrical pulses, sonic vibrations, mechanical pressure, and mixtures of substances, which may include drugs, proteins, antibodies, or liposomes, which can be combined, injected, or administered transdermally or orally. Other embodiments are described and shown.

Abstract: Polyglutamic acid (PGA) formulations are provided for use as a dermal filler. Also provided are methods of use of such formulations for treatment of cosmetic defects.

Abstract: Novel bacteriocins produced by novel bacterial strains are used for at least reducing the levels of colonization by at least one target bacteria in animals, especially poultry.

Abstract: A method to modulate MHC class I gene expression by modulating NLRC5 expression and/or NLRC5 activity in a subject is provided. The method comprises administering to the subject a compound HLA-A HLA-B that modulates NLRC5 expression and/or NLRC5 activity in an amount effective to modulates MHC class I gene expression. Also described is a screen for compounds that modulate NLRC5 expression. Candidate compounds are tested for their ability to modulate NLRC5 expression.

Abstract: Compositions containing a lactic acid-producing bacterial strain, e.g., Bacillus coagulans for inhibition of pathogenic bacterial infections. Spores or extracellular products produced by the bacterial strains are also useful as inhibitory agents.

Abstract: An object of the present invention is to find a novel and useful component in a culture supernatant of a lactic acid bacterium and to provide an effective utilization method of the component. The utilization method is a cytoprotective agent containing, as an active ingredient, a low-molecular-weight fraction in a culture supernatant of a lactic acid bacterium belonging to Streptococcus thermophilus.

Abstract: A sterile pharmaceutically acceptable aqueous solution, which solution is provided in a sealed container and comprises: a pharmaceutically acceptable aqueous solvent; viral particles or a physiologically active polypeptide; an excipient selected from a polyethyleneimine; a compound of formula (I) or a physiologically acceptable salt or ester thereof; or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and optionally, one or more sugars.

Abstract: The present invention relates to an isolated Lactobacillus paracasei bacterium, deposited as NRRL B-50314, that secretes a bacteriocin. More specifically, the bacteriocin has antibacterial activity against a range of Gram-positive bacteria, including but not limited to Listeria monocytogenes, Staphylococcus aureus, Enterococcus faecalis, and other Lactobacillus species. Additionally, the bacteriocin has antibacterial activity against methicillin resistant Staphylococcus aureus.

Abstract: Disclosed herein are antifouling compositions including at least one spinosyn active material. These compositions provide protection to surfaces coated or impregnated therewith from attachment of various biofouling organisms. Compositions include, for example, paint, varnish, and sealant formulations.

Abstract: The invention refers to use of Nocardia Rubra Cell Wall Skeleton, especially the new use of the same in the preparation of Anti-HPV medicaments.

Abstract: The present invention relates to a novel wild-type Lactococcus lactis subsp. cremoris bacteria strain with increased vitamin K2 production and mutants and variants thereof and methods for preparation of a fermented food or feed product enriched in vitamin K2 and a vitamin K enriched edible product for amelioration and/or prevention of vitamin K deficiency. The present invention also relates to the fermented food or feed product and the edible product obtainable by the methods herein and to the wild-type Lactococcus lactis subsp. cremoris bacteria strain for use in treatment and/or prevention of vitamin K deficiency in a mammal, such as a human.

Abstract: The present invention relates to novel mycobacterial compositions containing RNA and cell walls, and methods for making and using these compositions. These compositions have immune stimulating and anti-cancer activity. The present invention also relates to a synthetic medium for the cultivation of mycobacteria.

Abstract: Methods, compositions and bacterial isolates for improving the gastrointestinal health of animals and in particular of poultry are provided herein. The methods include administering an endospore-forming bacteria to an animal. The bacteria are selected for the ability to reduce the growth and presence of bacterial pathogens, such as Salmonella, Clostridium, and Campylobacter, in the gastrointestinal tract of the animal. The bacteria are also selected for the ability to improve at least one production parameter in the animal.

Abstract: The present invention is directed toward protecting the cosmetic use of at least an effective amount of a lysate of at least one microorganism of the genus Bifidobacterium species, or a fraction thereof, for preventing and/or treating body odor.

Abstract: The present invention relates to the fields of life sciences and food, feed or pharmaceutical industry. Specifically, the invention relates to novel peptides, pilus structures, polynucleotides as well as vectors, host cells, products and pharmaceutical compositions comprising the polynucleotides, peptides or pilus structures. The invention also relates to gene clusters and antibodies. Furthermore, the present invention relates to methods for producing the peptides or pilus structures or producing the products comprising the peptides or pilus structures. Furthermore, the present invention relates to treatments as well as uses and methods for screening bacterial strains, for reducing or inhibiting the adhesion of pathogenic bacteria, promoting the adhesion of bacterial cells to the mucus and for modifying immune response in a subject. Still, the present invention relates to methods for detecting probiotic bacterial strains or pathogen strains.

Abstract: An isolated microorganism comprising a Propionibacteria strain is described. When the microorganism is fed to a ruminant, protein and fat levels in milk produced by the ruminant are increased, while body condition and milk production levels are maintained. When fed to the ruminant, the microorganism also has positive effects on various metabolic hormones and metabolites, e.g, an increase in energy balance, plasma non-esterified fatty acids levels, and plasma leptin level. Supplementation with propionibacteria reduced dry matter intake but did not affect milk production in the cows. Therefore, the propionibacteria of the invention made the cows more energy efficient as cows produced the same amount of milk, yet consumed less dry matter.

Abstract: Provided is an isolated B. fragilis bacterial cell producing a native capsular polysaccharide A (PSA), wherein the cell is incapable of producing capsular polysaccharides PSB, PSC, PSD, PSE, PSF, PSG, and PSH because the cell's biosynthetic genes for native capsular polysaccharides PSB, PSC, PSD, PSE, PSF, PSG, and PSH have been deleted from the cell's genome. The isolated isolated or wild type B. fragilis cell, or an extract obtained from said B. fragilis cell, can be used to treat individuals with inflammation.

Abstract: The present invention generally relates to the field of obesity. In particular the present invention relates to the use of probiotics to treat obesity. One embedment of the present invention relates to the use of Lactobacillus rhamnosus CGMCC 1.3724 and/or Lactobacillus rhamnosus NCC 4007 for the preparation of a composition to support weight management, promote weight loss and/or to treat obesity.

Abstract: The invention relates to adhesives for medical applications and methods of their preparation and use.

Abstract: There is provided an anti-cancer composition comprising an aquatic microbial extract, and there is more particularly provided an anti-cancer composition comprising a Bacillus sp. strain extract.

Abstract: The invention comprises methods for diagnosing the risk of onset of type 1 diabetes and for preventing the onset of type 1 diabetes. The genetic background, metabolomes, antibodies and diversity of gut microbiota of an individual can be used for diagnosis.

Abstract: This invention provides an effective means or method for improving lipid metabolism, and a means or method for treatment or prevention of diseases or disorders associated with the lipid metabolism disorder. Specifically, this invention relates to an agent for improving the lipid metabolism comprising, as active ingredients, broken cells of a lactic acid bacterium, and to a method for enhancing an effect of a lactic acid bacterium for improving the lipid metabolism comprising a step of breaking the lactic acid bacterium.

Abstract: Improved efficacy in treatment of gastric disorders with botulinum toxin is obtained using liposomal encapsulated botulinum formulations for topical administration of the botulinum toxin. The liposomes are typically administered in a physiologically acceptable carrier such as saline or phosphate buffered saline by application onto the surface of the tissue within into the gastrointestinal (GI) tract in need of treatment. Preferably, the formulation is applied via a roller, sponge or nozzle that is attached to an endoscope.

Abstract: An object of the present invention is to provide a composition for removing aldehyde. Specifically, the present invention relates to an aldehyde-removing composition comprising a microorganism belonging to the genus Gluconobacter having aldehyde-degrading activity, or extracts thereof or disrupted cells thereof, wherein the microorganism belonging to the genus Gluconobacter has higher aldehyde-degrading activity than aldehyde-generating activity.

Abstract: It is to provide a composition derived from lactic acid bacteria having an anti-allergic effect (an effect of suppressing allergic symptoms such as hay fever) synergistically, and a food product, pet food, etc. containing the composition. It is to prepare a composition having an anti-allergic action, containing Lactobacillus crispatus KT-11 strain, KT-23 strain, or KT-25 strain bacterial cells and viable bacteria, dead bacteria, or a processed product of bacterial cells of other lactic acid bacteria belonging to the genus Lactobacillus, genus Bifidobacterium, genus Leuconostoc, genus Enterococcus, genus Pediococcus, etc. at a biomass-converted ratio of 99:1 to 50:50, preferably 99:1 to 75:25.

Abstract: A process including: (a) mixing a microbial biomass, comprising oil-containing microbes, and at least one grinding agent capable of absorbing oil, to provide a disrupted biomass mix; (b) blending at least one binding agent with said disrupted biomass mix to provide a fixable mix capable of forming a solid pellet; and, (c) forming the solid pellet from the fixable mix. The process optionally includes extracting the solid pellet with a solvent to provide an extracted microbial oil.

Abstract: The present invention relates to a novel antimicrobial protein derived from bacteriophage having killing activity specific to Staphylococcus aureus, more precisely an antimicrobial protein originated from Podoviridae bacteriophage having killing activity specific to Staphylococcus aureus which is the causing agent of infectious disease in human and animals, a pharmaceutical composition for the prevention and treatment of infectious disease caused by Staphylococcus aureus, an antibiotic and a disinfectant containing the bacteriophage-originated antimicrobial protein as an active ingredient.

Abstract: Fungicidal mixtures based on azolopyrimidinylamines.

Abstract: The present invention relates to an extract from bacterial strains useful as a treatment for disorders such as digestive or urinary tract disorders, compositions comprising the extract, and processes of making the extract from media that do not pose a risk of prion diseases.

Abstract: Disclosed is a novel cadherin peptide that enhances the toxicity of Cry proteins. A novel insecticide composition comprising an effective amount of cadherin peptide having SEQ. ID. NO:2 and an effective amount of Bacillus thuringiensis Cry protein wherein the cadherin peptide comprises a Cry3Aa toxin binding region from the full-length T. molitor cadherin and has synergistic characteristics of a binary toxin potentiating Cry3 and Cry1 toxins against coleopterans and lepidopteran species, respectively.

Abstract: The present invention relates to methods of treating esophageal spasms using botulinum toxins.

Abstract: The present invention provides a means and a method for effectively increasing Bifidobacteria in the large intestine. Specifically, the present invention relates to an agent for increasing Bifidobacteria and/or reducing the decrease of Bifidobacteria in the large intestine, which comprises spores of Bacillus subtilis and a means of delivering the spores to the large intestine of a subject while maintaining the spore form of Bacillus subtilis.

Abstract: The present invention describes novel nanoparticle compositions, and systems and methods utilizing them for treating disorders and/or conditions. Methods generally involve administering nanoparticle compositions (e.g., nanoparticle compositions comprising at least one known therapeutic agent and/or independently active biologically active agent; and/or empty nanoparticle compositions) to a subject in need thereof.

Abstract: Provided herein are methods of producing and processing a feedstock from a photosynthetic microorganism. Also provided are various transgenic photosynthetic microorganism and photobioreactors for use in the methods.

Abstract: The present invention embraces methods and kits for facilitating the propogation of PrPSc, and use of the same in increasing the sensitivity diagnostic assays and in identifying compounds that modulate the conversion of PrPc to PrPSc.

Abstract: The invention relates to the use of at least one probiotic microorganism as an active agent for preventing and/or treating impaired radiance of the skin's complexion.